02410 同源康醫藥－Ｂ
TYK MEDICINES-B
TYK MEDICINES-B
| Listing Date | 2024/08/20 |
| Listing Price | 12.100 |
Subscription Result
- Subscription Rate2.29x
- Guarantee One Lot Size3 lot
- One Lot Success Rate47.88%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
TYK Medicines, Inc is a clinical-stage biopharmaceutical company committed to the discovery, acquisition, development and commercialization of differentiated targeted therapies to address unmet medical needs in cancer treatment.
--
Since its inception in 2017, the Group has built a pipeline with 11 drug candidates, including Core Product TY-9591, six clinical stage products, and four preclinical stage products.
--
The Group is currently conducting a pivotal Phase II clinical trial of TY-9591 monotherapy as first-line treatment of brain metastases from non-small cell lung cancer (“NSCLC”) with epidermal growth factor receptor (“EGFR”) mutations in China, as well as a registrational Phase III clinical trial of TY-9591 monotherapy as first-line treatment in locally advanced (stage IIIb or IV) or metastatic NSCLC with EGFR L858R mutation in China.
--
The Group is in the process of establishing its in-house cGMP-compliant manufacturing facility in Huzhou, Zhejiang Province, which is expected to commence commercial-scale manufacturing by the end of 2025.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 47.88M H shares |
| No. of International Offer Shares | 43.09M H shares |
| No. of HK Offer Shares | 4.79M H shares |
| Offer Price | $12.10 |
| Stock Code | 2410 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | CLSA Limited, Deutsche Bank AG, Hong Kong Branch, CMB International Capital Limited, Haitong International Securities Company Limited, BOCI Asia Limited, Livermore Holdings Limited |
TIME TABLE
| Application Period | Aug 12 (Mon) - noon, Aug 15 (Thu) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Aug 19 (Mon) |
| Result Announcement Date | On or before Aug 19 (Mon) |
| Result Announcement Date | On or before Aug 20 (Tue) |
| Dealings in Shares commence on | Aug 20, 2024. (Tue) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $12.10 |
| Capitalization | 4.49B |
| NAV / share ($) | $1.89 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 12.10, the net proceeds raised would be HKD 506.30M, of which |
| 70% : Research, development and commercialization of Core Product, namely, TY-9591 |
| 20% : Research and development of other product candidates, including TY-302, TY-2136b, TY-1091, TY-4028, TY-2699a and TY-0540 |
| 3% : Potential strategic acquisition, investment, in-licensing or collaboration opportunities |
| 7% : Working capital |
IPO NEWS
| 20/08/2024 16:08 |
| {New Stock}TYK MEDICINES-B(02410) ends up 13.22% at HK$13.7 |
| 20/08/2024 09:20 |
| {New Stock}TYK MEDICINES-B opens up 19.67% at HK$14.48 |
| 19/08/2024 18:35 |
| {New Stock}TYK MEDICINES-B ends up 9.09% on grey market |
| 19/08/2024 16:20 |
| {New Stock}TYK MEDICINES-B up 7.44% at HK$13 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).